Trametinib (Norwegian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Trametinib" in Norwegian language version.

refsWebsite

Global rank Norwegian rank

3web.archive.org

1^st place

1^st place

1,684^th place

low place

low place

low place

49^th place

132^nd place

2,374^th place

3,358^th place

4^th place

23^rd place

2^nd place

9^th place

low place

low place

1dagensmedisin.no

low place

574^th place

asco.org

«METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM).». Arkivert fra originalen 16. januar 2013. Besøkt 4. november 2015.

cancer.gov

Trametinib, NCI Drug Dictionary

dagensmedisin.no

«Sier ja til BRAF- og MEK-hemmerne». Dagens Medisin. 25. april 2016.

doi.org

«Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations». 367 (18). New England Journal of Medicine. 1. november 2012: 1694–703. PMC 3549295 . PMID 23020132. doi:10.1056/NEJMoa1210093.

nejm.org

«Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations». 367 (18). New England Journal of Medicine. 1. november 2012: 1694–703. PMC 3549295 . PMID 23020132. doi:10.1056/NEJMoa1210093.

nih.gov

ncbi.nlm.nih.gov

«Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations». 367 (18). New England Journal of Medicine. 1. november 2012: 1694–703. PMC 3549295 . PMID 23020132. doi:10.1056/NEJMoa1210093.

onclive.com

«Dabrafenib/Trametinib Combination Approved for Advanced Melanoma». OncLive. 9. januar 2014. Arkivert fra originalen 25. januar 2014. Besøkt 4. november 2015.

reuters.com

«GSK melanoma drugs add to tally of U.S. drug approvals». Reuters. 30. mai 2013. Arkivert fra originalen 24. september 2015. Besøkt 4. november 2015.

web.archive.org

«METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM).». Arkivert fra originalen 16. januar 2013. Besøkt 4. november 2015.
«GSK melanoma drugs add to tally of U.S. drug approvals». Reuters. 30. mai 2013. Arkivert fra originalen 24. september 2015. Besøkt 4. november 2015.
«Dabrafenib/Trametinib Combination Approved for Advanced Melanoma». OncLive. 9. januar 2014. Arkivert fra originalen 25. januar 2014. Besøkt 4. november 2015.